biotech · Lupus Nephritis · Primary or Secondary Progressive Multiple Sclerosis · KYTX
Kyverna Therapeutics
Kyverna Therapeutics is a biotech organization headquartered in Emeryville, USA. It trades on NYSE under ticker KYTX. Primary therapeutic focus areas include Lupus Nephritis, Primary or Secondary Progressive Multiple Scl
5980 Horton St, Suite 550, Emeryville, California 94608, US HQ
2018 Founded
155 Employees
Public company Type
KYTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 5980 Horton St, Suite 550, Emeryville, California 94608, US
- Founded
- 2018
- Employees
- 155
- Programs
- 14
- Drugs
- 31
- Patents
- 2
CCM-RNT-202402
Phase 2 · small molecule · ANCA-IgG-positive ANCA Associated Vasculitis
CCM-RNT-202402 for ANCA-IgG-positive ANCA Associated Vasculitis is a Phase 2 program (small_molecule) at Kyverna Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CCM-RNT-202402
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Kyverna Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- ANCA-IgG-positive ANCA Associated Vasculitis
- Status
- active
- Trials
- 1